1 minute reading time (130 words)

Update on Immunotherapeutic Strategies for Recurrent and Metastatic Cervical Cancer: Bradley Monk, MD, FACS, FACOG, and Jennifer Filipi, MSN, FNP-C

There are an estimated 13,800 new cases of cervical cancer in the United States each year, and 4,290 people die of the disease (ACS, 2020). Deaths have declined during the past few decades due to screening and heightened awareness, yet this malignancy continues to be a global health concern and is considered an epidemic in parts of the world. A significant proportion of patients develop advanced disease, which is rarely curable with available therapies, and treatment is often limited to palliative care (NCCN, 2020). The 5-year overall survival rate is 56% for women with regional disease and 17% for those with distant disease; amongst black women, the prognosis is worse (Siegel et al, 2020).

Related Posts

Copyright © 2022 Oncology Data Advisor. All rights reserved.